Allurion Technologies Inc. (ALUR)
NYSE: ALUR · Real-Time Price · USD
0.348
+0.068 (24.33%)
Dec 20, 2024, 4:00 PM EST - Market closed
Allurion Technologies Revenue
Allurion Technologies had revenue of $5.37M in the quarter ending September 30, 2024, a decrease of -70.51%. This brings the company's revenue in the last twelve months to $34.75M, down -46.05% year-over-year. In the year 2023, Allurion Technologies had annual revenue of $53.47M, down -16.73%.
Revenue (ttm)
$34.75M
Revenue Growth
-46.05%
P/S Ratio
0.52
Revenue / Employee
$68,956
Employees
504
Market Cap
27.45M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 53.47M | -10.74M | -16.73% |
Dec 31, 2022 | 64.21M | 25.97M | 67.91% |
Dec 31, 2021 | 38.24M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionALUR News
- 19 days ago - Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance - Business Wire
- 26 days ago - Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program - Business Wire
- 5 weeks ago - Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society's Annual Conference - Business Wire
- 7 weeks ago - Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024 - Business Wire
- 2 months ago - Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon - Business Wire
- 2 months ago - October's 4 Best Penny Stocks: High-Risk, High-Reward Picks - Benzinga